The efficacy of selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) in older people: the state of the art

2008 ◽  
Author(s):  
Cornelius Katona ◽  
Amber Selwood
Keyword(s):  
Older People ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
State Of The Art ◽  
The State ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Noradrenaline Reuptake

Off-label uses of selective serotonin reuptake inhibitors (SSRIs)

2021 ◽  
Vol 19 ◽  
Author(s):  
Tommaso B. Jannini ◽  
Giorgio Di Lorenzo ◽  
Emanuela Bianciardi ◽  
Cinzia Niolu ◽  
Massimiliano Toscano ◽  
...  
Keyword(s):  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Premature Ejaculation ◽  
State Of The Art ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Regulatory Agencies ◽  
Psychiatric Evaluation ◽  
Off Label ◽  
Common Clinical Practice

: Psychiatric drugs have primacy for off-label prescribing. Among those, selective serotonin reuptake inhibitors (SSRIs) are extremely versatile and, therefore, widely prescribed. Moreover, they are commonly considered as having a better safety profile compared to other antidepressants. For these reasons, when it comes to off-label prescribing, SSRIs rank among the top positions. In this review, we present the state of the art of off-label applications of selective serotonin reuptake inhibitors, ranging from migraine prophylaxis to SARS-CoV-2 antiviral properties. Research on SSRIs provided significant evidence in the treatment of premature ejaculation, both with the on-label dapoxetine 30 mg and the off-label paroxetine 20 mg. However, other than serotoninergic syndrome, serious conditions like increased bleeding rates, hyponatremia, hepatoxicity, and post-SSRIs sexual dysfunctions, are consistently more prominent when using such compounds. These insidious side effects might be frequently underestimated during common clinical practice, especially by non-psychiatrists. For this reason, some points must be addressed when using SSRIs. Among these, a psychiatric evaluation before every administration that falls outside the regulatory agencies-approved guidelines has to be considered mandatory. For these reasons, we aim with the present article to identify the risks of inappropriate uses and to advocate the need to actively boost research encouraging future clinical trials on this topic.

Sign in / Sign up

Export Citation Format

Share Document